Posted: October 16th, 2019
Regional Court Düsseldorf (docket no. 4c O 22/19) and Higher Regional Court Düsseldorf (docket no. I-2 U 28/19) The Higher Regional Court Düsseldorf recently confirmed on appeal that Teva Pharmaceutical Industries Ltd. (“Teva”) is entitled to a preliminary injunction (“PI”) against Mylan dura GmbH (“Mylan”) in Germany. This PI relates to Mylan’s product CLIFT 40 […]
READ MORE
Posted: October 15th, 2019
Teva Pharmaceutical Industries Ltd., and Teva Denmark A/S (“Teva”) v. Mylan AB (“Mylan”), the Danish Maritime and Commercial High Court, Case number BS-38788/2018-SHR, 15 March 2019 The case concerns infringement of the patents DK/EP 2 949 335, DK/EP 2 630 962 and DK/EP 3 199 172, which are owned by Yeda Research & Development Company, […]
READ MORE
Posted: October 15th, 2019
Court of Appeals of Barcelona, 29 May 2019, Docket No. 1686/2018 On 29 May 2019, the Court of Appeals of Barcelona handed down a pioneering patent ruling in Spain, according to which, in interpretation of Article 42 of the Spanish Code of Civil Procedure, the national judge has the faculty to declare, in view of […]
READ MORE
Posted: October 14th, 2019
Mermet v. Chavanoz Industrie, cour d’appel de Lyon, 12 September 2019, Docket № 16/06896 By Pierre Véron, Honorary President, EPLAW On 12 September 2019, the cour d’appel de Lyon (court of appeal) overturned a judgment handed down on 8 September 2016 by the tribunal de grande instance de Lyon (court of first instance) which found […]
READ MORE
Posted: October 11th, 2019
Irreparable harm discussion sparks a new debate in Switzerland, by Simon Holzer and Kilian Schärli, Meyerlustenberger Lachenal Ltd. (MLL) In Switzerland, by tradition, the requirements for showing not easily reparable harm in order to obtain a preliminary injunction in patent matters have never been very high. This may be because in Switzerland ex-parte injunctions are […]
READ MORE
Posted: October 10th, 2019
Novartis Pharma AG, Novartis International Pharmaceutical AG, Novartis AG v. Teva Nederland B.V., Court of Appeal The Hague, The Netherlands, 17 September 2019, Case No. ECLI:NL:GHDHA:2019:2648 Novartis holds substance patent EP 0 663 916 relating to everolimus, an immonosuppressant, as well as six divisionals relating to ‘cancer treatment’. Teva holds a Dutch marketing authorisation for […]
READ MORE
Posted: October 9th, 2019
A Practitioner’s Guide to European Patent Law, For National Practice and the Unified Patent Court, Hart Publishing, 17 October 2019 Written by Paul England (Taylor Wessing), with contributions from Judith Krens (Taylor Wessing), Sara Burghart (Sandoz) and François Pochart (August Debouzy) From the blurb: “Written by a team of lawyers with long-standing experience in patent […]
READ MORE
Posted: October 8th, 2019
“High-growth technology business conference 2019 – Boosting your strategy with intellectual property” is the first-ever conference to be jointly organised by the European Patent Office and the Licensing Executives Society International (LESI), with support of Enterprise Ireland. The event, which will be held in Dublin on 4-5 November 2019, provides a platform for high-growth technology […]
READ MORE
Posted: October 1st, 2019
Enlarged Board of Appeal, G 2/19, decision of July 16, 2019, reported by Dr. Rudolf Teschemacher, Bardehle Pagenberg In its decision T 831/17 of February 25, 2019, Technical Board of Appeal 3.5.03 referred questions to the Enlarged Board of Appeal (EBA) concerning the right to oral proceedings of an appellant who is not party to […]
READ MORE
Posted: October 1st, 2019
The Munich IP Dispute Resolution Forum organizes an event to be held in Munich on 12 November entitled: “GEMA TYPE AGENCIES AS A SOLUTION FOR FRAND? “ The event is a joint initiative of the Max Planck Institute and Judge Zigann of the Landgericht Munich. From the website: “In the meeting it will be discussed […]
READ MORE
EMAIL US
